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DNA vaccines can induce impressive speciﬁc cellular immune response (IR) when taking advantage of their
recognition as pathogen-associated molecular patterns (PAMP) through Toll-like receptors (TLR) expressed on/in
cells of the innate immune system. Among the many types of PAMP, immunostimulatory DNA, so-called CpG
motifs, was shown to interact speciﬁcally with TLR9, which is expressed in plasmacytoid dendritic cells (pDC), a
key regulatory cell for the activation of innate and adaptive IR. We now report that CpG motifs, when introduced into
the backbone, are a useful adjuvant for plasmid-based DNA (pDNA) vaccines to induce melanoma antigen-speciﬁc
protective T cell responses in the Cloudman M3/DBA/2 model. The CpG-enriched pDNA vaccine induced protection
against subsequent challenge with melanoma cells at signiﬁcantly higher levels than its parental unmodiﬁed
vector. Preferential induction of an antigen-speciﬁc, protective T cell response could be demonstrated by (i)
induction of antigen-dependent tumor cell protection, (ii) complete loss of protection by in vivo CD4þ /CD8þT cell-
but not NK cell-depletion, and (iii) the detection of antigen-speciﬁc T cell responses but not of relevant NK cell
activity in vitro. These results demonstrate that employing PAMP in pDNA vaccines improves the induction of
protective, antigen-speciﬁc, T cell-mediated IR.
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Most tumors express antigens (TAA) in the context of major
histocompatibility molecules (MHC) that can be recognized
by the adaptive arm of the immune system. There is now a
considerable body of data from animal models and human
cells in vitro that indicates that T cells are the major effector
cell population for the immunological control of TAA-
expressing tumor cells (reviewed in Rosenberg, 2001; Finn,
2003). Nonetheless, tumors frequently escape spontaneous
recognition and subsequent destruction by the immune
system. Failure to generate optimal tumor antigen-specific
T cell responses may be one reason for this phenomenon
(Finn, 2003). In the case of melanoma, several groups of
TAA have been identified so far, including the so-called
melanocytic differentiation antigens (MDA) such as Pmel17/
gp100 (Cox et al, 1994; Kawakami et al, 1995; Wagner et al,
1995). The identification of these antigens now allows the
development of active immunization strategies to either
induce or enhance antigen-specific T cell responses. The
optimal immunization strategy for inducing such cellular
immune responses (IR) in humans remains undefined and
animal models of melanoma may be a valuable tool to test
various vaccine formulations (Finn, 2003).
Plasmid-based DNA (pDNA) vaccines have not just been
able to induce antibody but also cellular IR in laboratory
animals and in humans (reviewed in Donnelly et al, 1997).
In humans, this has been demonstrated particularly for
pathogen-derived antigens with the induction of antigen-
specific antibody as well as T cell responses (Wang et al,
1998; Tacket et al, 1999; Roy et al, 2000; Wang et al, 2001)
that in a prime-boost strategy with modified vaccinia virus
Ankara may also translate into T cell-mediated protective
immunity (McConkey et al, 2003). In melanoma patients,
lymph node infusion of pDNA vaccines led to the induction
of antigen-specific T cells (Tagawa et al, 2003) and
intratumoral injection led to regression of tumors at distant
sites in a minor proportion of patients (Stopeck et al, 1997).
A recurring observation made in all these clinical trials is that
although it appears possible to induce cellular IR with pDNA
vaccines in humans, relatively high doses of DNA are
required to elicit detectable but still weak IR (Calarota et al,
1998; Wang et al, 1998; Tagawa et al, 2003). Therefore,
strategies to optimize the immunogenicity of pDNA vac-
cines are clearly needed. One strategy to modulate
significantly the immunological efficacy of a vaccine is the
use of adjuvants, particularly if the immunogenicity of a
given antigen is limited, as in the case of TAA (Cohen et al,
1998).
Bacterial extracts are known as potent activators of both
innate and adaptive IR and are recognized by the immune
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system via ‘‘pattern-recognition receptors’’ that are ex-
pressed on distinct cells of the innate immune system. The
so-far best-characterized member of ‘‘pattern-recognition
receptors’’ is the Toll-like receptor (TLR) family. TLR9 is
expressed in the endosomal compartment exclusively of
plasmacytoid dendritic cells (pDC) and B cells in humans
and, in addition, on myeloid DC and monocytes/macro-
phages in mice (Kadowaki et al, 2001; Krug et al, 2001;
Ahmad-Nejad et al, 2002; Hornung et al, 2002). It is now
known that the molecular structure recognized in bacterial
extracts by TLR9 consists of unmethylated CpG dinucleo-
tides in certain base contexts, the so-called CpG motifs
(Krieg et al, 1995; Krieg, 2003). When present in synthetic
oligonucleotides (ODN), CpG motifs are able to enter the
lysosomal compartment of pDC within minutes of exposure,
where these motifs interact specifically with TLR9. Down-
stream signaling involves the adapter molecule MyD88 and
ultimately leads to activation of pDC and maturation into
professional antigen-presenting cells (Krug et al, 2001).
These express co-stimulatory molecules, the chemokine
receptor CCR7, and secrete Th1-promoting chemokines
and cytokines such as IP-10 and type I interferon (IFN)
(reviewed in Krieg, 2002). Within hours, secondary effects
such as NK cell activation, enhanced expression of Fc
receptors on polymorphonuclear leukocytes, and an in-
crease in antibody-dependent cellular cytotoxicity (ADCC)
are induced. This stimulation of the innate immune system
with activation/maturation of pDC and antigen presentation
in a Th1-like cytokine milieu can induce primary CD8 T cell
responses even in the absence of CD4 T cell help (Wild et al,
1999; Sparwasser et al, 2000).
We have previously examined an animal model of
melanoma to define the prerequisites necessary for and
the mechanisms involved in the induction of protective
immunity by an antigen-specific pDNA vaccine (Wagner et al,
2000). The goal of this study was to determine whether CpG
motifs can act as an adjuvant to the induction of antigen-
specific cytotoxic T lymphocyte (CTL) responses against a
weakly immunogenic TAA delivered as pDNA vaccine and if
this translates into enhanced protective immunity against
melanoma cells. The results obtained suggest that the
introduction of CpG motifs into backbone sequences of
the vector represents a promising strategy to enhance the
immunogenicity of pDNA-based cancer vaccines.
Results
pUK21-A2 vector and its CpG-enriched variant pMCG16
exhibit comparable transgene expression levels To
check whether the modification of the pDNA vector for its
content of CpG motifs may have altered expression levels
of the transgene, we transfected COS-7 cells with either
pUK21-A2/EGFP or pMCG16/EGFP and, 48 h later,
compared their EGFP-fluorescence levels as a function of
transgene expression (EGFP, enhanced green fluorescent
protein). FACS analysis revealed that both vectors yielded
similar transfection efficiencies with regard to the frequency
of transfected cells as well as transgene expression levels
(Fig 1). These results confirm that the enrichment of CpG
motifs into vector pUK21-A2 had no direct effect on
transgene expression.
Protective anti-tumor activity of pDNA vaccines is
signiﬁcantly augmented by CpG motifs The generation
of Cloudman S91 M3-derived melanoma sublines M3-7
(Pmel17/gp100þ ) and M3-1 (Pmel17/gp100) has been
described earlier (Wagner et al, 2000). S.c. inoculation of
5  105 cells of both sublines into syngeneic DBA/2 mice
regularly results in the appearance of exponentially growing
tumors at the injection site without subsequent formation of
macroscopically detectable visceral metastasis.
To compare pDNA vectors pUK21-A2/mPmel17 and
pMCG16/mPmel17 for their ability to induce anti-tumor
immunity, mice received two injections of the respective
constructs and were subsequently challenged with Pmel17/
gp100þ M3-7 cells. Twelve of 26 animals (46.2%) immu-
Figure 1
Intracellular expression level of enhanced
green fluorescent protein (EGFP) in COS
cells after transfection with CpG-enriched
pMCG16 and non-CpG-enriched pUK21-A2
pDNA. Fifty percent confluent COS cells were
transfected with either pUK21-A2/EGFP or
pMCG16/EGFP. Their EGFP fluorescence was
compared 48 h later by FACS analysis. Expres-
sion levels of the EGFP transgene from the
parental pUK21-A2 vector (middle) are compar-
able with those derived from the CpG-enriched
pMCG16 vector (bottom). Mock-transfected
COS cells served as negative control (top).
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nized with CpG-enriched pMCG16/mPmel17 pDNA were
completely protected against the highly tumorigenic dose of
5  105 Pmel17/gp100þ M3-7 cells (pooled results of two
sets of experiments). None of the protected animals
developed a tumor at a later time point during the entire
observation period of 4 mo (Fig 2A). By contrast, injection
with pUK21-A2/mPmel17 pDNA prevented the growth of
the M3-7 inoculum in only four of 22 mice (18%, Fig 2A,
po0.01). In sharp contrast, control animals that had been
injected with either vector only (empty vectors) consistently
failed to reject Pmel17/gp100þ M3-7 melanoma cells
(po0.001 for both pairs, Fig 2B).
The protective anti-tumor host response triggered by
CpG motifs is antigen-speciﬁc Mice received two intra-
dermal injections of the parental pUK21-A2/mPmel17
construct, its CpG-enriched variant pMCG16/mPmel17, or
either vector only and were subsequently challenged with
5  105 Pmel17/gp100 M3-1 melanoma cells. In contrast
to the protection observed against the Pmel17/gp100þ M3-
7 cells as a function of CpG content of mPmel17-encoding
pDNA vectors, neither pUK21-A2/mPmel17 (six of six ani-
mals) nor pMCG16/mPmel17 pDNA (nine of nine animals)
were able to protect the animals against a challenge with
antigen-negative M3-1 melanoma cells (Fig 3A,B). All
animals developed tumors as did the vector-only injected
(Fig 3A,B) or naı¨ve control mice.
Antigenic specificity of the protective immunity induced
by CpG motifs in pDNA-based vaccines was addressed in a
further set of experiments. Animals that had developed
protective anti-tumor immunity after vaccination with CpG-
enriched pMCG16/mPmel17 pDNA, as demonstrated by
successful rejection of Pmel17/gp100þ M3-7 cells, were
challenged with syngeneic but histogenetically unrelated
Pmel17/gp100 P815 mastocytoma cells. Similar to non-
immunized control mice, none of these animals (zero of six)
was able to reject this tumor cell inoculum (Fig 4). Taken
together, these results indicate that the protective anti-
tumor host response induced by CpG-enriched pMCG16/
mPmel17 pDNA is antigen-specific.
Figure 2
Increased protection against melanoma cell challenge obtained
after genetic vaccination with a CpG-enriched plasmid-based DNA
(pDNA) vector construct. Mice were injected interdermally into one
side of the back with 100 mg of either pUK21-A2/mPmel17 or pMCG16/
mPmel17 pDNA constructs, twice in a 2-wk interval. Two weeks later,
animals were challenged contralaterally into the back by s.c. implanta-
tion of 5  105 Pmel17/gp100þ M3-7 melanoma cells. Although about
50% of DBA/2 mice immunized with CpG-enriched pMCG16/mPmel17
pDNA were protected against a subsequent challenge with Pmel17/
gp100þ M3-7 melanoma cells, only about 18% of animals vaccinated
with non-modified pUK21-A2/mPmel17 pDNA showed complete
protection (po0.01) (A). Control animals—injected with either vector
alone (empty pMCG16 or pUK21-A2 pDNA) according to the protocol
described above—consistently failed to reject Pmel17/gp100þ M3-7
melanoma cells (B).
Figure3
Administration of CpG-enriched pMCG16 plasmid-based DNA
(pDNA) coding for Pmel17 protects animals against the growth of
melanoma cells in an antigen-specific manner. Mice were injected
with pMCG16/mPmel17 pDNA twice and subsequently challenged with
Pmel17/gp100 M3-1 melanoma cells according to the protocol
described under Materials and Methods. In contrast to the protection
rates observed against a challenge with Pmel17/gp100þ M3-7
melanoma cells (Fig 2A), none of the animals was able to reject
Pmel17/gp100 M3-1 melanoma cells nor were control-treated mice
injected with empty pMCG16 pDNA alone (A). The same observation
was made for mice immunized with non-enriched pUK21-A2/mPmel17
pDNA and the animals injected with the respective control pUK21-A2
vector pDNA alone when challenged with Pmel17/gp100 M3-1
melanoma cells (B).
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The protective anti-tumor effect triggered by CpG motifs
requires the adaptive arm of the immune system To
characterize the effector mechanisms triggered by CpG
motifs present in pDNA-based vaccines, we performed T
cell- and NK cell-depletion experiments. Animals that had
received two injections of CpG-enriched pMCG16/
mPmel17 were depleted of either CD4þ /CD8þ T lympho-
cytes or NK cells before being challenged with Pmel17/
gp100þ M3-7 melanoma cells. In this experiment, eight of
eight CD4þ /CD8þ T cell-depleted animals developed
tumors, indicating that the protective anti-tumor effect
otherwise induced by the CpG-enriched pDNA construct
was completely dependent on the presence of T lympho-
cytes (Fig 5). In contrast, NK cell depletion resulted in only a
minor, if any, loss of the animals’ ability to reject Pmel17/
gp100þ M3-7 melanoma cells (three protected of seven
immunized animals) as compared with non-NK cell-
depleted, pMCG16/mPmel17-immunized animals (four pro-
tected of nine immunized animals, Fig 5). Taken together,
these results demonstrate that mainly T cells represent the
critical effector population of protective anti-tumor host
responses elicited by application of CpG-enriched antigen-
specific pDNA constructs.
To confirm the stimulatory effect of CpG motifs in pDNA-
based vaccines on the adaptive arm of the immune system
more directly, CTL assays were performed. Splenocytes
from pUK21-2A/mPmel17 and pMCG16/mPmel17 immu-
nized as well as vector-only injected animals were tested for
the presence of Pmel17/gp100-specific CTL. Spleen cells of
animals injected with the CpG-enriched pMCG16/mPmel17
pDNA exhibited significant lysis of Pmel17/gp100þ M3-7
target cells whereas they failed to kill Pmel17/gp100 M3-1
cells (Fig 6A). By contrast, neither M3-7 nor M3-1 cells were
significantly lyzed by spleen cells from naı¨ve control animals
(Fig 6B). YAC-1 lysis at significant levels was not detected
in these assays (Fig 6C), which excluded a significant
contribution of NK cell activity on killing of M3-7 melanoma
cells. Together with the demonstration that both M3-7 and
M3-1 cells are similarly susceptible to the cytotoxic activity
of lymphokine-activated killer (LAK) cells as well as allo-
specific CTL (data not shown), these results suggest that
killing of Pmel17/gp100þ M3-7 cells obtained with spleno-
cytes from animals immunized with CpG-enriched pMCG16/
mPmel17 pDNA is executed by Pmel17/gp100-specific T
lymphocytes.
In these CTL assays, splenocytes from animals immu-
nized with CpG-enriched pMCG16/mPmel17 pDNA were
consistently found to exhibit a more pronounced (1.5–2 titer
levels) antigen-specific CTL activity than splenocytes from
animals injected with pUK21-2A/mPmel17 pDNA (see Fig
6A,D). To further confirm this observation, we performed
genetic vaccination with pUK21-A2/b-galactosidase and
pMCG16/b-galactosidase pDNA vectors according to the
protocol described above. Induced antigen-specific T cell
numbers were quantitatively evaluated with the help of
ELISPOT assays using the b-galactosidase encoded, H2d-
restricted immunodominant peptide TPHPARIGL. In these
assays, splenocytes derived from mice immunized with
CpG-enriched pMCG16 pDNA vector again exhibited
reproducibly higher frequencies of antigen-specific IFN-g-
secreting T cells than splenocytes derived from mice immu-
nized with the parental pDNA vector pUK21-2A (Fig 7).
Discussion
There are several strategies to enhance the potential of
pDNA vaccines for the induction of an effective IR. These
strategies include the facilitation of pDNA uptake into and
release within targeted cells, e.g. by complexing with
polycations/lipopolyplexes or electroporation, enhance-
ment of the nuclear association of transgenes or targeting
Figure 4
Growth characteristics of syngeneic Pmel17/gp100 P815 masto-
cytoma cells. Mice were injected with pMCG16/mPmel17 plasmid-
based DNA (pDNA) twice and subsequently challenged with Pmel17/
gp100þ M3-7 melanoma cells according to the protocol described
under Materials and Methods. Mice that had successfully rejected this
melanoma cell inoculum were challenged 8 wk later by the s.c.
inoculation of 1  105 syngeneic Pmel17/gp100 P815 mastocytoma
cells. Note that animals consistently developed tumors upon injection
of Pmel17/gp100 P815 cells. These tumors grew at a rate comparable
with that observed in control mice injected with empty pMCG16 pDNA
(control mice).
Figure5
Tumor cell protection is mediated by T cells but not NK cells. Mice
were injected with pMCG16/mPmel17 pDNA twice in a 2-wk interval
and challenged 14 d later with Pmel17/gp100þ M3-7 melanoma cells.
To deplete T cells, animals received i.p. injections of anti-CD4 (0.3 mg
GK1.5) and anti-CD8 (0.3 mg YTS169) antibody solutions at days 3,
2, and 1 before tumor cell challenge. To deplete NK cells, mice
were injected i.p. on days 1, þ1, 6, 11, 16, 21, 26, and 31 around
tumor cell challenge with 200 mL of a 1:10 PBS dilution of a
reconstituted anti-asialo-GM1 preparation. Animals were monitored
for the appearance and growth of tumors as described above. Note
complete loss of tumor protection in mice depleted of CD4þ and
CD8þ T cells, but not in mice depleted of NK cells.
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to antigen-presentation pathways, modification to antigens,
and increase in immunogenicity by use of adjuvants (over-
view in Donnelly et al, 2003; Herweijer and Wolff, 2003). For
the latter objective, the classical rules of application of
adjuvants to proteins are not transferable to DNA vaccines
due to significant differences of antigen expression in terms
of time kinetics and quantitative levels obtained. Thus,
many adjuvants effective in protein-based immunization
strategies are not or not as effective for DNA vaccines
(reviewed in Spack and Sorgi, 2001). Consequently,
identification of adjuvants augmenting the activity of pDNA
vaccines is a major challenge for the successful develop-
ment of DNA vaccines.
Replication-deficient viral vectors, particularly adenoviral
vectors, can induce impressive specific cellular IR by taking
advantage of their recognition as pathogen-associated
molecular patterns (PAMP) through TLR expressed on/in
cells of the innate immune system. But the frequent
generation of impressive memory responses against the
vector itself considerably inhibits the boost of an IR against
the encoded transgene by repetetive application (St
George, 2003). Among the many types of PAMP, immunos-
timulatory DNA motifs have been shown to interact
specifically with TLR9, which is expressed in CD123þ
pDC (Bauer et al, 2001a; Bauer et al, 2001b), a key
regulatory cell for the activation not only of innate but also
Figure 6
Intracutaneous genetic immunization with CpG-enriched pMCG16/mPmel17 plasmid-based DNA (pDNA) results in the generation of an
antigen-specific CTL response. Splenocytes, recovered 2 wk after the second immunization from pUK21-A2/mPmel17, pMCG16/mPmel17
recipients, and naı¨ve control mice, respectively, were restimulated for 4 d with interferon (IFN)-g- and PFA-treated Pmel17/gp100þ M3-7 cells. Lysis
of target cells mediated by restimulated splenocytes was determined in a 5 h standard 51Cr-release assay. Target cells included Pmel17/gp100þ
M3-7, Pmel17/gp100 M3-1 melanoma cells (both pre-stimulated with 100 U per mL IFN-g for 18 h) and YAC-1 cells. In these assays, splenocytes
from mice immunized with CpG-enriched pMCG16/mPmel17 pDNA lysed Pmel17/gp100þ M3-7 melanoma cells at significant levels whereas
Pmel17/gp100 M3-1 melanoma cells were not lysed (A). Neither M3-7 nor M3-1 melanoma cells were lysed by splenocytes derived from naı¨ve
mice (B). NK cell target cells YAC-1 were lysed at irrelevant levels by splenocytes derived from mice injected with CpG-enriched pMCG16/mPmel17
pDNA as well as pUK21-A2/mPmel17 pDNA (C). CTL activity of splenocytes derived from animals injected with pUK21-2A/mPmel17 pDNA
(D) recorded consistently lower levels (1.5–2 titer levels) of Pmel17/gp100þ M3-7 lysis when compared with levels obtained with splenocytes from
animals injected with CpG-enriched pMCG16/mPmel17 pDNA (A). Standard deviations of triplicates wereo5% and have been omitted from figures
for clarity.
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of adaptive IR (Arpinati et al, 2003). In this study, we now
demonstrate that modification of the backbone sequence of
a pDNA vaccine for the presence of this subgroup of PAMP
results (i) in a significantly increased protection against a
subsequent, otherwise lethal, challenge with antigen-posi-
tive, but not antigen-negative syngeneic melanoma cells, (ii)
in the induction of a protective T cell but not NK cell
response in vivo as demonstrated by in vivo cell depletion
assays, (iii) in the detection of an increased and antigen-
dependent target cell lysis by Tcells but not NK cells in vitro,
and (iv) in the detection of increased numbers of antigen-
specific, IFN-g-secreting T cells.
Anti-tumor effects of immunostimulatory CpG motifs,
particularly in the form of CpG ODN, have been described
against various tumor types when applied with or without
antigen or antibodies (Carpentier et al, 2000; Lanuti et al,
2000; Ballas et al, 2001; Kawarada et al, 2001; Miconnet
et al, 2002; Zwaveling et al, 2002; Baines and Celis, 2003;
Baral et al, 2003; Davila et al, 2003; Sandler et al, 2003). This
may be the result of the induction and/or enhancement of
different effector mechanisms. In most of these models, the
anti-tumor effect of CpG motifs was mediated via activation
of the innate immune system directly through NK cells, but
enhancement of ADCC (Wooldridge et al, 1997) and, more
recently, induction of adaptive cellular IR have also been
described (Ballas et al, 2001; Miconnet et al, 2002;
Zwaveling et al, 2002; Baines and Celis, 2003; Davila et al,
2003). Using the B16/C57BL/6 melanoma model, Ballas
et al (2001) described induction of anti-tumor immunity with
regression of established melanomas by application of CpG
ODN 1585. The protection of TAP-1- and b2-microglobulin-
knockout mice to a degree similar to normal C57BL/6, lack
of immunological memory in surviving animals, and loss of
protection after in vivo NK cell depletion strongly suggest
the stimulation of an NK cell-mediated effector mechanism.
Several of our findings make it very unlikely that this effector
mechanism is also operative in the M3/DBA/2 mouse
melanoma model. These include the lack of abrogation of
protective effects in NK cell depletion experiments, the lack
of significant NK cell activity in CTL assays, and the inability
of mice injected with the CpG-enriched vector-only con-
struct to reject melanoma cells. In contrast, the protection
against antigen-positive, but not antigen-negative melano-
ma cells, the loss of anti-tumor protection by in vivo T cell
depletion assays, and the presence of antigen-specifc CTL
indicate the stimulation of antigen-specific T cell-mediated
immunity. These observations are in agreement with the
results described in the B16/C57BL/6 melanoma model and
the transgenic HHD mouse model when using CpG motifs,
namely CpG ODN 1826, along with melanoma antigens
provided as peptides (Miconnet et al, 2002; Davila et al,
2003). In combination immunotherapy with an antibody
blocking the interaction of CTLA-4 on T cells with its ligands
B7.1 and B7.2, which may provide negative signals to T
cells, application of CpG ODN plus MDA TRP2180–188 CTL
epitope induced therapeutic immunity that required both
CD4þ and CD8þ T cells (Davila et al, 2003). Furthermore,
human human Db mice, which are transgenic for chimeric
human HLA-A0201/mouse Db MHC class I molecules,
mounted antigen-specific and cytolytic CD8þ T cell
responses after application of a peptide analog of human
MDA MART-1/Melan-A26–35 in the presence of CpG ODN
1826 (Miconnet et al, 2002). The different kinds of IR
triggered by CpG motifs in these melanoma models may be
due to the different genetic background of the animal
models used; however, there may be additional explana-
tions including the different routes of application of the
compounds (i.p. vs s.c.) (Cohen et al, 1998) and, most
importantly, the type of CpG motif used. CpG ODN 1826
and 1585 significantly differ in their ability to induce cytokine
secretion and NK cell activation in C57BL/6 splenocytes.
Although CpG ODN 1826 induces high levels of Interleukin
(IL)-6, IL-12, IFN-g, and tumor necrosis factor-a, a cytokine
pattern that may favor the induction of Th1-biased T cell
responses, CpG ODN 1585 is a much more potent inducer
of NK cell activity (Ballas et al, 2001). These differential
immunostimulatory properties are now known to represent
a direct function of sequence composition and backbone
modification of ODN (Krieg, 2002).
Several observations derived from systems employing
model antigens (Mor et al, 1995; Sato et al, 1996; Tighe et al,
1998) have supported the view that increasing the number
of CpG motifs in pDNA may indeed result in the induction of
more effective cellular IR. Our results obtained with the
model antigen b-galactosidase are in accordance to those
described by Sato et al (1996), who demonstrated that
application of a b-galactosidase-encoding vector modified
for its selectable marker, i.e. substitution of the CpG-poor
kanamycinR gene by the CpG-rich ampicillinR gene, results
in a much more efficient induction of antigen-specific T
cell responses. Our results support these data and extend
them by two further observations: (i) the significant adjuvant
Figure 7
Induction of antigen specific T cell responses as measured by
ELISPOT assay. Mice were immunized with pUK21-A2/b-galactosi-
dase or pMCG16/b-galactosidase plasmid-based DNA (pDNA) accord-
ing to the protocol described for the mPmel17-containing pDNA
constructs. Ten days after the second injection, splenocytes were
collected from immunized recipients as well as from naı¨ve control mice
and restimulated with an H-2d-restricted b-galactosidase peptide
TPHPARIGL overnight. In this assay, splenocytes from mice immunized
with CpG-enriched pMCG16/b-galactosidase pDNA (pMCG16/b-gal)
exhibited consistently higher frequencies of IFN-g-secreting Tcells than
those derived from mice immunized with parental unmodified pUK21-
A2/b-galactosidase pDNA (pUK21-A2/b-gal). Background levels were
observed in splenocytes from naı¨ve animals (naı¨ve). Values are given for
0.25  106 splenocytes.
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effect on the induction of T cell activity against a weakly
immunogenic (non-model, non-viral) self-antigen and
(ii) the translation of this IR into enhanced protective can-
cer immunity. Even though pDNA vectors cannot be directly
compared with CpG ODN for the immunostimulatory effects
induced, the immunological phenomena described in this
study support the assumption that the backbone modifica-
tions of the pDNA vector have resulted in an adjuvant effect
comparable with that described for CpG ODN 1826. This
study extends our knowledge on these immunostimulatory
properties of antigen-specific pDNA vaccines and supports
the concept of enhancing the immunogenicity of DNA
vaccines by modification with PAMP.
Materials and Methods
Mice Female 6–10-wk-old DBA/2 (H-2d) mice were purchased
from Charles River Wiga GmbH (Sulzfeld, Germany) and held under
specific pathogen-reduced conditions in the Central Animal
Laboratory (University of Essen, Germany). All animal experiments
were approved by the regulatory committee on animal welfare in
the state of Northrhine-Westfalia and the Austrian Ministry of
Science and Transportation.
Cell lines Clone M3 (derived from Cloudman S91 melanoma; H-
2d) (Yasumura et al, 1966), P815 mouse mastocytoma (H-2d), YAC-
1, and COS-7 cells were obtained originally from the American
Type Culture Collection (ATCC) (Rockville, Maryland). M3 melano-
ma cells were cultured in Ham’s F10 medium (Life Technologies,
Grand Island, New York) supplemented with 2.5% heat-inactivated
fetal calf serum (FCS) (Gibco BRL, Eggenstein, Germany), 12.5%
horse serum (Life Technologies), 0.1 mM non-essential amino
acids (Gibco BRL), 25 mM HEPES, 2 mM L-glutamine, 1 mM
sodium pyruvate, and 5  105 M 2-ME (Life Technologies) in
gelatin-coated culture flasks (Becton Dickinson, Heidelberg,
Germany). The generation of M3 sublines, Pmel17/gp100þ M3-7
(495% of cells immunoreactive with Pmel17/gp100-reactive mAb
HMB45), and Pmel17/gp100 M3-1 cells (o5% of cells immunor-
eactive with mAb HMB45) has been described previously (Wagner
et al, 2000). Pmel17/gp100 expression of these cells was regularly
checked by FACS analysis or immunostaining of cytospin
preparations. YAC-1 and P815 cells were cultured in RPMI 1640
(Life Technologies) supplemented with 10% FCS, HEPES, non-
essential amino acids, L-glutamine, sodium pyruvate, and 2-ME.
COS-7 cells were grown in DMEM supplemented with 10% FCS.
All cells were cultured at 371C in a humidified 5% CO2 atmosphere.
Construction of pDNA vectors and in vitro transcription/
translation analysis of introduced transgenes The pDNA vector
pUK21-A2 contains the immediate early promoter of human
cytomegalovirus (CMV IE), the bovine growth hormone poly-
adenylation signal, and the kanamycin resistance gene (Krieg
et al, 1998). The vector backbone of pUK21-A2 was modified
by eliminating 52 of 134 neutralizing CpG (-N) and addition of 16
immunostimulatory CpG (-S) motifs, thereby generating its variant
pDNA vector pMCG16. Briefly, site-directed mutagenesis by
overlap-extension PCR (Prosch et al, 1996) was employed to
introduce a total of 22 point mutations into the kanamycin
resistance gene and non-essential DNA backbone sequences
after the gene. Fifteen CpG-N motifs containing 19 CpG dinucleo-
tides were modified, 12 of which were eliminated and seven of
which were transformed into CpG-S motifs. All the mutations were
confirmed by sequencing. Another 37 CpG-N motifs were removed
by replacing a 0.6 kb NarI–EcoO109I fragment containing the F1
origin with an artificial multiple cloning site consisting of a 35 bp
double-stranded DNA fragment containing four unique restriction
enzyme sites (DraI, ScaI, AvaII, HpaI) (Krieg et al, 1998). Additional
nine CpG-S motifs were inserted into the vector by self-ligation of a
20 bp DNA fragment (50-GACTCCATGACGTTCCTGACGTTTCCA
TGACGTTCCTGACGTTG-30) with a complementary strand and
insertion of these copies into the AvaII site of the vector. Vector
sequences have been deposited in GenBank under accession
numbers AFO53408 and AFO53406.
pUK21-A2/mPmel17 and pMCG16/mPmel17 pDNA were gen-
erated by ligation of the 1.9 kb murine full-length Pmel17 cDNA
sequence (Schreurs et al, 1997; Zhai et al, 1997) into the respective
NotI cloning sites of pUK21-A2 and pMCG16 vectors. Full-length
pUK21-A2/b-galactosidase and pMCG16/b-galactosidase vectors
(MacGregor and Caskey, 1989) and pUK21-A2/EGFP and pMCG16/
EGFP encoding EGFP were generated accordingly. Correct
orientation and sequence of the respective transgenes were
confirmed by automated sequencing on an ABI PRISM genetic
analyzer (PE Biosystems, Weiterstadt, Germany) or restriction
enzyme mapping (EGFP). All pDNA constructs were affinity purified
with the Endo-free Plasmid Mega Kit (Qiagen, Hilden, Germany)
and all pDNA constructs contained o0.04 IU per mg of endotoxin,
as determined by the Limulus Amoebocyte Lysate Assay kit (QCL-
1000, BioWhittaker, Walkersville, Maryland).
Two micrograms of each vector construct was transfected into
50% confluent COS-7 cells using the DEAE dextran/chloroquine
diphosphate method essentially as described (Wagner et al, 1995).
After 48 h of incubation, transgene expression was assessed either
by FACS analysis (EGFP, Coulter-Immunotech, Krefeld, Germany),
immunocytochemistry with anti-Pmel17/gp100 Ab HMB45, or
enzymatic cleavage of 5-bromo-4-chlor-3-indolyl-b-D-galctopyra-
noside (X-Gal) for b-galactosidase activity.
Genetic vaccination and tumor challenge DBA/2 mice were
injected intradermally on one side of the shaved back with 100 mg
of pUK21-A2/mPmel17 and pMCG16/mPmel17 pDNA constructs,
twice in a 2-wk interval. Control animals received 100 mg vector
pDNA alone. Two weeks later, animals were challenged contral-
aterally into the back by s.c. implantation of 5  105 Pmel17/
gp100þ M3-7 or Pmel17/gp100 M3-1 cells. Tumor growth was
monitored every 2–3 d. All in vivo experiments were read in a
blinded, randomized fashion.
In an additional set of experiments, Pmel17-immunized animals
that had successfully rejected a M3-7 melanoma inoculum were
challenged 8 wk after implantation of M3-7 cells with the s.c.
inoculation of 1  105 syngeneic P815 mastocytoma cells.
In vivo cell depletion To deplete T cells, animals received i.p.
injections of anti-CD4 (0.3 mg GK1.5) and anti-CD8 (0.3 mg
YTS169) antibody solutions at days 3, 2, 1 before the tumor
cell challenge as described (Luhrs et al, 2002). This treatment led to
a 495% reduction of splenic CD3-positive cells as determined by
FACS analysis (not shown). Fourteen days after the second
vaccination, mice were inoculated s.c. with 5  105 Pmel17/
gp100þ M3-7 melanoma cells and monitored for the appearance
and growth of tumors as described above. A rabbit anti-asialo-
GM1 Ig preparation (Wako Chemicals, Neuss, Germany) was used
to deplete mice of NK cells as described (Schneeberger et al,
1999). Mice were injected i.p. on days 1, þ 1, 6, 11, 16, 21, 26,
and 31 around tumor cell challenge with 200 mL of a 1:10
phosphate-buffered saline (PBS) dilution of the reconstituted
anti-asialo-GM1 preparation. This treatment led to a 490%
reduction of the splenic NK cell activity (as assumed by lysis of
the NK cell target YAC-1) as compared with spleen cells of non-
treated mice or mice injected with a dialyzed 1:10 dilution of
normal rabbit serum (ICN Pharmaceuticals, Costa Mesa, California)
in PBS.
Cytotoxicity assay Splenocytes (4  106 per well), recovered
2 wk after the second immunization from pUK21-A2/mPmel17 and
pMCG16/mPmel17 recipients or from naı¨ve control mice, were
co-cultured for 4 d with 1  105 IFN-g (200 U per mL for 18 h;
Genzyme, Framingham, Massachusetts)-stimulated and PFA-
treated (0.5% PFA for 10 min at 371C) M3-7 cells as described
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(Wagner et al, 2000). Recombinant human (rh) IL-2 (Cetus Corp.,
Emeryville, California) was added at a final concentration of 10 U
per mL. Lysis of target cells mediated by restimulated splenocytes
was determined in a 5 h standard 51Cr-release assay. For this
purpose, 5  103 Na2 [51Cr]O4 (ICN, Eschwege, Germany)-labeled
target cells were incubated with splenocytes at various effector-
to-target ratios in triplicate U-bottomed 96-well plates (Greiner,
Solingen, Germany) in a final volume of 200 mL. 51Cr released from
the targets into the supernatant was quantified in a liquid
scintillation counter (Beckman LS-6000, Munich, Germany). Target
cells included Pmel17/gp100þ M3-7 and Pmel17/gp100 M3-1
melanoma cells (both pre-stimulated with 100 U per mL IFN-g for
18 h) and YAC-1 cells used as control for NK cell activity within
the spleen cell populations. To generate LAK cells, splenocytes of
naı¨ve animals were cultured for 5 d in complete medium supple-
mented with 200 U per mL rhIL-2 (Cetus Corp.). The percentage of
specific lysis was calculated as [(sample c.p.m.spontaneous
c.p.m./(maximal c.p.m.spontaneous c.p.m.)]  100. Sponta-
neous release in all cases ranged between 10% and 20% of the
maximum release obtained by treatment of labeled target cells with
1% Triton X-100 (Sigma, Deisenhofen, Germany).
ELISPOT assay Mice were immunized intracutaneously two times
in 2 wk interval with pUK21-A2/b-galactosidase or pMCG16/b-
galactosidase pDNA according to the protocol described for the
mPmel17-containing pDNA constructs. Ten days later, splenocytes
were collected from immunized recipients as well as from naı¨ve
control mice. Multiscreen 96-well assay plates (Millipore, Bredford,
Massachusetts) were pre-coated overnight at 41C with 5 mg per mL
anti-IFN-g antibody R4-6A2 (Schmitt et al, 1994) in 0.1 M sodium
carbonate buffer pH 9.3. After washing with PBS/0.05% Tween-20,
plates were blocked for 2 h with DMEM standard medium (Gibco
BRL). Splenocytes were plated in duplicate at a density of 2  106
per 100 mL in DMEM standard medium. For restimulation, 100 mL of
the H-2d-restricted b-galactosidase peptide (TPHPARIGL) at a final
concentration of 20 mg per mL was added. Plates were cultured
overnight at 371C, 5% CO2, washed extensively, and incubated
with 100 mL of the biotinylated anti-IFN-g mAb AN18.17.24 (2 mg
per mL; Schmitt et al, 1994) for 2 h. Detection was carried out
with peroxidase conjugated to streptavidin at a dilution of 1/5000
(Boehringer Mannheim, Mannheim, Germany). After 1 h of incu-
bation with peroxidase-conjugated streptavidin (dilution of 1:5000,
Boehringer Mannheim), spots were developed by adding 100 mL of
substrate (0.8 mg per mL 3,30-Diaminobenzidine (Sigma)/0.4 mg
per mL NiCl2 (Sigma)/0.009% H2O2 in 0.1 M Tris pH 7.5) and the
reaction was stopped after 10–30 min by washing with deionized
H2O. Spots were counted subsequently with the ELISPOT
Bioreader-2000 (Biosys GmbH, Karben, Germany).
Statistical analysis Fisher’s exact test was used to evaluate
statistical differences in tumor protection rates between pUK21-
A2/mPmel17 and pMCG16/mPmel17-immunized mice as well as
to evaluate differences with the respective control vector-treated
mice.
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